Abstract
ObjectiveThis study represents the first 10 year analysis of the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of early low-risk prostate cancer.Materials and methodsTwo hundred and thirty males were treated with Cyberknife SBRT to a dose of 35 Gray (Gy) or 36.25 Gy in five consecutive days. All patients had a Gleason score of six and a PSA < 10ng/ml. Median follow-up is nine years. The median age was 69.5 years and median prostate specific antigen (PSA) was 5.6ng/ml. The treatment was delivered with homogeneous planning with a dose prescription of 82-87% of the maximum dose to cover the planning target volume (PTV).ResultsTen-year biochemical disease free survival was 93% with either dose. Local control was 98.4%. Median prostate specific antigen (PSA) dropped to 0.1 by five years and has remained there. Toxicity was mild with 10% of patients having Grade two-three late urinary toxicity and 4% having the late grade two rectal toxicity. Mean Expanded Prostate Cancer Index Composite (EPIC) Quality of Life (QOL) scores declined initially for bowel and urinary domains, but recovered to baseline, where they remain. EPIC sexual scores have declined by 40%.Discussion/ConclusionsStereotactic body radiotherapy to a dose of 35 Gy-36.25 Gy is an effective treatment for early low-risk prostate cancer, with acceptably low toxicity. There appears to be no benefit to increasing the dose beyond 35 Gy. Ten-year biochemical disease free survival appears to be higher than with standard intensity modulated radiotherapy (IMRT).
Highlights
Over the last 10 years, many reports of stereotactic body radiotherapy (SBRT) treatments for early prostate cancer, in which high fractional doses are delivered in four or five fractions, have appeared in the literature [1,2,3,4,5,6,7]
The outcomes to date have been favorable, a legitimate concern is that the reported follow-up is not long enough to identify all the benefits and pitfalls of this treatment. We address these concerns by reporting a large cohort of low-risk patients with up to 10-years of follow-up
All patients were planned with a computerized tomography (CAT) scan fused with a magnetic resonance imaging (MRI) scan
Summary
Over the last 10 years, many reports of stereotactic body radiotherapy (SBRT) treatments for early prostate cancer, in which high fractional doses are delivered in four or five fractions, have appeared in the literature [1,2,3,4,5,6,7]. The effects of doses of 35 Gy to 50 Gy in five fractions have been assessed. With follow-up up to seven years, these studies, mostly involving low- and intermediate- risk patients have shown excellent biochemical control with low rates of toxicity. How to cite this article Katz A (September 09, 2017) Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
